Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Michael Birrer to Clinical Trials as Topic

This is a "connection" page, showing publications Michael Birrer has written about Clinical Trials as Topic.

 
Connection Strength
  
 
 
1.340
  
  1. Fountain J, Trimble E, Birrer MJ. Summary and discussion of session recommendations. Gynecol Oncol. 2006 Nov; 103(2 Suppl 1):S23-5.
    View in: PubMed
    Score: 0.233
  2. Farley J, Bast RC, Birrer MJ. Biomarkers and clinical trial design. Gynecol Oncol. 2006 Nov; 103(2 Suppl 1):S3-5.
    View in: PubMed
    Score: 0.233
  3. Makhlouf H, Watson MA, Lankes HA, Weil C, Dickler M, Birrer M, Moskaluk C, Ramirez NC, Okby N, Alonsozana E, Barnes M, Goldman EB, Enos R, Lubensky I. Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. Am J Clin Pathol. 2020 01 02; 153(2):149-155.
    View in: PubMed
    Score: 0.146
  4. Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-Drug Conjugate-Based Therapeutics: State of the Science. J Natl Cancer Inst. 2019 Jun 01; 111(6):538-549.
    View in: PubMed
    Score: 0.140
  5. Birrer MJ, Betella I, Martin LP, Moore KN. Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age? Oncologist. 2019 04; 24(4):425-429.
    View in: PubMed
    Score: 0.137
  6. Wei W, Dizon D, Vathipadiekal V, Birrer MJ. Ovarian cancer: genomic analysis. Ann Oncol. 2013 Dec; 24 Suppl 10:x7-15.
    View in: PubMed
    Score: 0.096
  7. Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G. Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era. Int J Gynecol Cancer. 2013 Oct; 23(8):1528-34.
    View in: PubMed
    Score: 0.095
  8. Ledermann JA, Marth C, Carey MS, Birrer M, Bowtell DD, Kaye S, McNeish I, Oza A, Scambia G, Rustin G, Stehman FB, Gershenson D, Thomas G, Berns E, Casado A, Ottevanger N, Hilpert F, Kim BG, Okamoto A, Bacon M, Kitchener H, Stuart GC. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer. 2011 May; 21(4):763-70.
    View in: PubMed
    Score: 0.080
  9. Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M, Thomas GM, Kitchener HC, Aghajanian C, Alberts DS, Armstrong D, Brown J, Coleman RL, Colombo N, Eisenhauer E, Friedlander M, Fujiwara K, Hunsberger S, Kaye S, Ledermann JA, Lee S, Look K, Mannel R, McNeish IA, Minasian L, Oza A, Paul J, Poveda A, Pujade-Lauraine E, Schoenfeldt M, Swart AM, von Gruenigen V, Wenzel L. Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int J Gynecol Cancer. 2010 Oct; 20(7):1290-8.
    View in: PubMed
    Score: 0.077
  10. Farley J, Birrer MJ. Novel therapeutic targets. Cancer Treat Res. 2009; 149:63-84.
    View in: PubMed
    Score: 0.068
  11. Randall LM, Birrer MJ, Herzog TJ. Ovarian Cancer Maintenance: Practice-Changing Data Calls for Changing Practice. Oncologist. 2019 05; 24(5):576-579.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.